A phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 3, 2008, Pages 499-508

  Fakih, Marwan G ^a,b   Pendyala, Lakshmi ^a   Brady, William ^a   Smith, Patrick F ^c   Ross, Mary E ^a   Creaven, Patrick J ^a,b   Badmaev, Vladimir ^d   Prey, Joshua D ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d Sabinsa Incorporation   (United States)

Author keywords

Colon cancer; Irinotecan; Pharmacokinetics; Phase I; Selenomethionine

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; DEXAMETHASONE; IRINOTECAN; LOPERAMIDE; MITOMYCIN; NITROSOUREA; PALONOSETRON; SELENIUM; SELENOMETHIONINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD LEVEL; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL ADENOMA; CONSTIPATION; CONTROLLED STUDY; CYST; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FEVER; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SIDE EFFECT; SODIUM BLOOD LEVEL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SELENOMETHIONINE; TREATMENT OUTCOME;

EID: 45849123896     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0631-4     Document Type: Article

References (25)

1. Schrauzer GN, White DA, Schneider CJ (1977) Cancer mortality correlation studies-III: statistical associations with dietary selenium intakes. Bioinorg Chem 7(1):23-31
2. Clark LC, Cantor KP, Allaway WH (1991) Selenium in forage crops and cancer mortality in U.S. counties. Arch Environ Health 46(1):37-42
3. Helzlsouer KJ, Comstock GW, Morris JS (1989) Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. Cancer Res 49(21):6144-8
4. Burney PG, Comstock GW, Morris JS (1989) Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. Am J Clin Nutr 49(5):895-900
5. Glattre E et al (1989) Prediagnostic serum selenium in a case-control study of thyroid cancer. Int J Epidemiol 18(1):45-9
6. Jaskiewicz K et al (1988) Selenium and other mineral elements in populations at risk for esophageal cancer. Cancer 62(12):2635-9
7. Gerhardsson L et al (1985) Protective effect of selenium on lung cancer in smelter workers. Br J Ind Med 42(9):617-26
8. Miyamoto H et al (1987) Serum selenium and vitamin E concentrations in families of lung cancer patients. Cancer 60(5):1159-62
9. Reinhold U et al (1989) Serum selenium levels in patients with malignant melanoma. Acta Derm Venereol 69(2):132-6
10. Westin T et al (1989) Circulating levels of selenium and zinc in relation to nutritional status in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 115(9):1079-82
11. Criqui MH et al (1991) Selenium, retinol, retinol-binding protein, and uric acid. Associations with cancer mortality in a population-based prospective case-control study. Ann Epidemiol 1(5):385-93
12. Hardell L et al (1995) Levels of selenium in plasma and glutathione peroxidase in erythrocytes in patients with prostate cancer or benign hyperplasia. Eur J Cancer Prev 4(1):91-5
13. Clark LC et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Jama 276(24):1957-63
14. Duffield-Lillico AJ et al (2003) Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 95(19):1477-81
15. Last KW et al (2003) Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma. J Clin Oncol 21(12):2335-41
16. Cao S, Durrani FA, Rustum YM (2004) Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 10(7):2561-9
17. Azrak RG et al (2007) Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. Biochem Pharmacol 73(9):1280-7
18. Fakih M et al (2005) Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer 5(2):132-5
19. Fakih MG et al (2006) A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. Clin Cancer Res 12(4):1237-44
20. Rothenberg ML et al (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11(11):2194-204
21. Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-16
22. Ip C (1998) Lessons from basic research in selenium and cancer prevention. J Nutr 128(11):1845-54
23. Goulet AC et al (2007) Profiling of Selenomethionine Responsive Genes in Colon Cancer by Microarray Analysis. Cancer Biol Ther 6(4)
24. Fischer JL et al (2007) Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther 6(1):355-61
25. Zhao R, Domann FE, Zhong W (2006) Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells. Mol Cancer Ther 5(12):3275-84